title: Experience of treating high risk prostate hyperplasia patients with a HPS120 laser.
abstract: BACKGROUND
  The aim of this study was to investigate the effects and safety of 120 watt PVP surgery for the high risk prostate hyperplasia patients.
  
  
  METHODS
  120 watt PVP surgery was performed on 120 cases of high risk prostate hyperplasia patients. The assessment included the operation time, energy consumed, hemoglobin changes, and serum salt concentration, whether to keep urinary catheter, hospitalization time, and complications after the operation. International Prostate Symptom Scoring (IPSS), the maximum urine flow rate (Qmax) and residual urine volume (RUV) were conducted preoperatively and postoperatively for the patients.
  
  
  RESULTS
  There were 30% of patients taking oral anti-coagulant drug (n = 36), 88 cases with abnormal ECGs. All the patient's internal diseases, include the cardiovascular disease (42/120), the hypertension (56/120), the respiratory system diseases (51/120), the cerebrovascular diseases (39/120), anemia (24/120), liver or kidney dysfunction (16/120), diabetes (18/120), hypoproteinemia (15/120) were under controlled. The average age, prostate volume and energy consumed was 82.8 ± 8.6 (70-96) years, 66.1 ± 25.3 (30-160) ml, and 224 ± 85 (31-596) kJ respectively. The average follow-up time was 20.8 ± 3.2 (18-24) months. The incidence of bladder neck contracture and urethral stricture were 1.7% and 0.8% respectively, no prostate cancer occurred during the subsequent follow-up period.
  
  
  CONCLUSIONS
  120 watt PVP surgery can safely and effectively alleviate the urination parameters of high risk prostate hyperplasia patients. The surgical process is safe and effective, and is not affected by the various internal diseases or the use of oral anti-coagulant drugs.
authors.affiliation: Deptment of Urology, 307 Hospital of PLA, Beijing 100071, China. lijunchencn@163.com.
authors.forename: Li-Jun
authors.initials: LJ
authors.lastname: Chen
authors.forename: Hai-Xing
authors.initials: HX
authors.lastname: Mai
authors.forename: Li
authors.initials: L
authors.lastname: Zhao
authors.forename: Nan
authors.initials: N
authors.lastname: Qu
authors.forename: Ya-Lin
authors.initials: YL
authors.lastname: Wang
authors.forename: Chen
authors.initials: C
authors.lastname: Huang
authors.forename: Xue-Chao
authors.initials: XC
authors.lastname: Li
authors.forename: Jin-Kai
authors.initials: JK
authors.lastname: Dong
authors.forename: Fei
authors.initials: F
authors.lastname: Tang
authors.forename: Biao
authors.initials: B
authors.lastname: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002681:China; D015897:Comorbidity; D006801:Humans; D053685:Laser Therapy / Q000706:statistics & numerical data*; D059411:Lower Urinary Tract Symptoms / Q000453:epidemiology* / Q000517:prevention & control*; D008297:Male; D011183:Postoperative Complications / Q000453:epidemiology*; D015995:Prevalence; D011470:Prostatic Hyperplasia / Q000453:epidemiology* / Q000601:surgery*; D012307:Risk Factors; D016896:Treatment Outcome; D014570:Urologic Diseases / Q000453:epidemiology*